Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (June 2017)
20 slides from Aurobindo Pharma's investor presentation, June 2017
Slide 1: Leading Vertically Integrated Generic Player
LEADING VERTICALLY INTEGRATED GENERIC PLAYER Investor Presentation June 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any
Slide 3: Executive Summary
Executive Summary Among the Top-3 listed pharmaceutical companies from India by sales(1) 6th largest generic company by volume in the US(2); IMS TRx represents greater than 28% growth year over year (3) Broad portfolio of diversified dosage forms including Rx and OTC oral solids, liquids, inje
Slide 4: Emerged into a leading global generic player
Emerged into a leading global generic player 2007 2017* Revenue 21.2 150.9 (Rs. Billion) EBITDA margin (%) 14.2% 22.8% Formulations 31% 80% contribution US Formulations 7% 45% contribution EU Formulations 6% 22% contribution Manufacturing 9 facilities including 3 23 facilities including 12 facilitie
Slide 5: The Journey So Far…
The Journey So Far… 2013 Commenced marketing specialty injectables in USA Building capabilities in Penem and Oncology 2006-08 Acquired UK based Milpharm 2014 Acquired formulations facility Acquired Western European in US commercial operations from Investment in building Actavis manufactu
Slide 6: Core Strengths
Core Strengths Scale & Operational Customer Leadership Strengths Centricity • Large manufacturing • High vertical integration • Global marketing network facilities inspected by in over 150 countries leading regulatory bodies • Robust and highly scalable formulations • Customer centric approach • Wel
Slide 7: Diversified Revenue Base & Strong Organic growth
Diversified Revenue Base & Strong Organic growth APIs, 20% US, 45% US, 30% APIs, 43% Revenue of ARV, 8% Revenue of Rs. 58.6 Billion Rs. 150.9 Billion Growth Markets *, 5% EU, 8% Growth EU, 22% ARV, 13% Markets*, 7% FY13 27% CAGR FY17** *major markets include Brazil, South Africa, Ukraine, and Mexico
Slide 8: Financial Performance
Financial Performance Revenue (Rs. Cr) EBITDA & PAT Margin (%) EPS (Rs/Share) EBITDA Margin PAT Margin 15,090 13,955 26.4 12,121 22.8 22.8 21.2 8,100 15.2 14.5 14.5 15.3 13.0 5,855 5.0 FY13 FY14** FY15 FY16* FY17* FY13 FY14** FY15 FY16* FY17* Gross Block & Fixed Asset Turnover Average ROE & ROCE % N
Slide 9: Our Business Segments
Our Business Segments US EU Ranked 6th* Rx supplier as per Among top 15** Gx companies IMS total prescriptions dispensed by sales Differentiated pipeline with new Focus markets are France, launches including injectables, Germany, Netherlands, Spain, ophthalmics, speciality products UK, Portu
Slide 10: US Business Overview
US Business Overview Aurobindo USA AuroMedics AuroLife Pharma AuroHealth Natrol Oral Rx Injectables Manufacturing / Pharma OTC Dietary Supplements R&D Cumulative ANDA Filings and Approvals 429 Addressable 398 Therapy ANDAs Market Size 376 (US$ Bn) 336 115 Anti Diabetic 13 5.4 147 ARV* 39 8.0 269 183
Slide 11: US: Expanding Portfolio Mix Towards Differentiated Products
US: Expanding Portfolio Mix Towards Differentiated Products Unit wise ANDA Filings as on 31-March-2017 Final Tentative Under Site Details Total Approval Approval Review Unit III Oral Formulations 100 16 10 126 Unit IV Injectables & Ophthalmics 41 2 35 78 Unit VIB Cephalosphorins Oral 11 11 Unit VII
Slide 12: Enhanced Research & Development Capabilities
Enhanced Research & Development Capabilities 5 R&D centers in Hyderabad, India Focus on building Focused on difficult to develop API, niche oral, sterile and specialty injectable differentiated product portfolio Concentrating on wide range of Oncology, Hormonal products, Penems, Enzymes, Biocata
Slide 13: EU Business Overview
EU Business Overview France Germany Netherlands Spain UK Portugal Italy Romania Belgium Revenue (Rs. Cr) India’s Leading Gx company with strong footprint in Europe Operations in 9 countries with full fledged sales force & support infrastructure 3,600 63% CAGR in FY13 –26FY17 30 22 Significant
Slide 14: EU: Portfolio Mix Across Channels
EU: Portfolio Mix Across Channels Sales split by Channel Sales split by Therapeutic Profile Sales split by Dosage Forms Dermatology Others 5% 10% CVS & Respiratory Antineo 27% plastic 7% Digestive Anti- CNS 15% infective 22% 14% Channels Gx BGx Hx TGx Germany, Spain Geographies All 9 countries 7 cou
Slide 15: ARV Business Overview
ARV Business Overview Focus on global tenders floated by Multi-Lateral Organizations like Revenue (Rs. Cr) Global Fund, USAID/PEPFAR and Country specific MOH tenders; currently caters to 2.2 million HIV+ patients 1,400 12% CAGR in FY13 – FY17 15 1,200 13 Well integrated supply chain management s
Slide 16: Growth Markets Business Overview
Growth Markets Business Overview Canada Ukraine GCC Countries Myanmar Mexico Tanzania Colombia Brazil South Africa Growth Markets Growth Drivers in the next 3-4 years Revenue (Rs. Cr) 800 7 16% CAGR in FY13-17 8 700 6 Build branded generics presence 600 5 5 756 5 6 500 646 Enhance penetration in
Slide 17: The Base Business: API
The Base Business : API Strong Regulatory Capability* API business continue to focus on high value, specialty, small/mid- size products with a limited competition Others Ensures quality & reliability of supplies and ability to command 8% cost efficiencies as well as economies of scale CoS 384
Slide 18: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-15 Mar-16 Dec-16 Mar-17 Closing Rate1 US$ = 62.50 66.255 67.925 64.85 INR Fx Loan restated in 4,312.3 4,956.7 3,593.7 3,121.5 690 748 529 481 INR Rupee Loan 37.3 46.9 61.9 244.8 Sales Tax Deferment 54.9 41.9 0.5 0.0 Gross Debt 4,404.5 5,045.6 3,656
Slide 19: Initiatives to Support Sustainable Future Growth
Initiatives to Support Sustainable Future Growth Short Term Medium Term Long Term Focus on strengthening the Portfolio, Commercial Drivers: Focus on launches Focus on increasing and sustaining the Capability and Capacity as Growth Drivers Peptides number of filings and launches of high- Additional
Slide 20: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725401 +91 98486 67906 Email: ir@aurobindo.com Corporate Office: Water Mark Building, Level-6, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Registered Of